Literature DB >> 3495188

CSF corticotropin-releasing hormone in depressed patients and normal control subjects.

A Roy, D Pickar, S Paul, A Doran, G P Chrousos, P W Gold.   

Abstract

The authors studied CSF corticotropin-releasing hormone (CRH) and plasma cortisol in 22 depressed patients and 18 normal control subjects. CRH levels were similar in the two groups. Depressed patients who were nonsuppressors on the dexamethasone suppression test had significantly higher levels of CRH than suppressors did. The depressed patients' CRH levels were significantly correlated with 4:00 p.m. postdexamethasone plasma cortisol levels. While the inclusion of a depressed patient with an outlier CRH value resulted in the loss of statistical significance for both of these findings, the authors suggest that these results support the hypothesis that hypercortisolism in depressed patients in part reflects a defect at or above the hypothalamus, resulting in hypersecretion of CRH.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495188     DOI: 10.1176/ajp.144.5.641

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  15 in total

Review 1.  The role of corticotropin-releasing factor and noradrenaline in stress-related responses, and the inter-relationships between the two systems.

Authors:  Adrian J Dunn; Artur H Swiergiel
Journal:  Eur J Pharmacol       Date:  2008-01-26       Impact factor: 4.432

2.  Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone.

Authors:  M L Wong; M A Kling; P J Munson; S Listwak; J Licinio; P Prolo; B Karp; I E McCutcheon; T D Geracioti; M D DeBellis; K C Rice; D S Goldstein; J D Veldhuis; G P Chrousos; E H Oldfield; S M McCann; P W Gold
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications.

Authors:  L S Brady; H J Whitfield; R J Fox; P W Gold; M Herkenham
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

Review 4.  Alterations in neuropeptides in aging and disease. Pathophysiology and potential for clinical intervention.

Authors:  A Leake; I N Ferrier
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

Review 5.  Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.

Authors:  Andrea H Marques; Marni N Silverman; Esther M Sternberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

6.  Psychological factors in asthma.

Authors:  Ryan J Van Lieshout; Glenda Macqueen
Journal:  Allergy Asthma Clin Immunol       Date:  2008-03-15       Impact factor: 3.406

Review 7.  [Immunological aspects of depressive disorders].

Authors:  N Müller; M J Schwarz
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

Review 8.  Neurosteroids in the context of stress: implications for depressive disorders.

Authors:  Susan S Girdler; Rebecca Klatzkin
Journal:  Pharmacol Ther       Date:  2007-05-24       Impact factor: 12.310

9.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

10.  Effects of the altered serotonergic signalling by neonatal treatment with 5,7-dihydroxytryptamine, ritanserin or clomipramine on the adrenocortical stress response and the glucocorticoid receptor binding in the hippocampus in adult rats.

Authors:  T Ogawa; M Mikuni; Y Kuroda; K Muneoka; K J Mori; K Takahashi
Journal:  J Neural Transm Gen Sect       Date:  1994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.